KRAS mutations (G12D, G12V, G12W, R68S, H95D and Y96C), high-level amplifications of the KRAS G12C allele and alterations in RAS-related pathways (MET amplification, BRAF V600E mutation, MAPK2K1/MEK1 E102_I103 deletion and PI3KCA H1047R mutation) were found in tissue biopsy samples and/or circulating tumor DNA obtained from KRAS G12C-mutant NSCLC patients who had acquired resistance to adagrasib [16]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.